**Acosta 2007** Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. *Antimicrob Agents Chemother* 2007, 51(9): 3104-3110.

**Agarwala 2003** Agarwala S, Grasela D, Child M, Geraldes M, Geiger M, O’Mara E. Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour 
dosing interval. Poster presented at *2nd International AIDS Society Conference on HIV Pathogenesis and Treatment*, Paris, 2003. (http://www.medadvocates.org/resources/conferences/iasconfpath/ias2003/atv%20pk%20past%2024%20hour%20interval.pdf), accessed on 07-30-2019.

**Agarwala 2005a** Agarwala S, Eley T, Child M, Wang Y, Hughes E, Grasela D. Pharmacokinetic effects of coadministration of atazanavir and tenofovir at steady state. Poster presented at *3rd International AIDS Society Conference on HIV Pathogenesis and Treatment*, Rio de Janeiro, 2005a. (http://www.medadvocates.org/resources/conferences/3rd%20_ias/05-156a_agarwala_086.pdf), accessed on 07-30-2019.

**Agarwala 2005b** Agarwala S, Gray K, Eley T, Wang Y, Hughes E, Grasela D. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects. Poster presented at *3rd International AIDS Society Conference on HIV Pathogenesis and Treatment*, Rio de Janeiro, 2005b. (http://www.medadvocates.org/resources/conferences/3rd%20_ias/05-156b_agarwala_109.pdf), accessed on 07-30-2019

**Berlin 2015** Berlin M, Ruff A, Kesisoglou F, Xu W, Wang MH, Dressman JB. Advances and challenges in PBPK modeling–analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base. *Eur J Pharm Biopharm* 2015, 93: 267-280.

**drugbank** (https://www.drugbank.ca/drugs/DB01072), accessed on 07-30-2019.

**Fricke 2020** Fricke R. Vericiguat: Investigations on Binding of Atazanavir to Recombinant UGT1A1 and of Mefenamic Acid to Recombinant UGT1A9. 2020. Report-No. PH-41346.

**Hyland 2008** Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of 
drug–drug interaction potential. *Br J Clin Pharmacol* 2008, 66(4): 498-507.

**Jungmann 2019** Jungmann N. Vericiguat: Determination of Ki Values of Atazanavir on 3-Glucuronidation of 17β-Estradiol via UGT1A1 and of Mefenamic Acid on Glucuronidation of Propofol via UGT1A9. Bayer AG Nonclinical study report. 2019 Aug. Report-No. PH-41095.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied concepts in PBPK modeling: how to build a PBPK/PD model. *CPT Pharmacometrics Syst Pharmacol* 2016, 5(10): 516-531.

**Le Tiec 2005** Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of 
efficacy and tolerability of atazanavir. *Clin Pharmacokinet.* 2005, 44(10): 1035-1050.

**Martin 2008** Martin DE, Galbraith H, Schettler J, Ellis C, Doto J. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. *Clin Ther.* 2008, 30(10): 1794-1805.

**Open Systems Pharmacology Documentation**. (https://docs.open-systems-pharmacology.org/), accessed on 07-30-2019.

**Perloff 2005** Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. *Drug Metab Dispos* 2005, 33(6): 764-770.

**PK-Sim Ontogeny Database Version 7.3**. (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf), accessed on 07-30-2019.

**Rodgers 2005** Rodgers T, Leahy D, Rowland M. Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases. *J Pharm Sci* 2005, 94: 1259-1275.

**Rodgers 2006** Rodgers T, Rowland M. Physiologically Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions. *J Pharm Sci* 2006, 95: 1238-1257.

**US Food and Drug Administration**. Reyataz (atazanavir) capsules: Clinical Pharmacology and Biopharmaceutics Review, Application number: 21-567, 2002. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021567_reyataz_toc.cfm, accessed on 07-30-2019.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.

**Zhu 2010** Zhu L, Butterton J, Persson A, Stonier M, Comisar W, Panebianco D, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. *Antivir Ther* 2010, 15(8): 1107-1114.

**Zhu 2011** Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, et al. Effect of low‐dose omeprazole (20 mg Daily) on the pharmacokinetics of multiple‐dose atazanavir with ritonavir in healthy subjects. *J Clin Pharmacol* 2011, 51(3): 368-377.